The enrichment of proliferative and metabolic pathways, coupled with the suppression of genes linked to angiogenesis and hypoxia, suggests that SIGLEC9 may support cancer cell adaptation to challenging tumor conditions without engaging processes like angiogenesis. The gene discussed is SIGLEC9; the disease is neoplasm.